~~<i id='BBD17FC9A3'><strike id='BBD17FC9A3'><tt id='BBD17FC9A3'><pre id='BBD17FC9A3'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

author：hotspot 2025-09-27 21:51:57 Page View：7

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 'Revelatory' study finds a smoking impact that remains after quitting
Next article： Alkermes shareholders re

leisure time

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Why did Pfizer dish out millions for a Super Bowl ad?

Pfizer'sSuperBowladshowedcompanyfoundersCharlesPfizerandCharlesErhartsingingQueen’s“Don’tStopMeNow"a

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Readout Newsletter: Bristol, Sangamo, Gilead, and more

EricRisberg/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsl

WSS

knowledge

knowledge

Featured Speakers

focus

leisure time

Readout Newsletter: Bristol, Sangamo, Gilead, and more